Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 11:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 27,820 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 3 Interventional

Gluten Sensitivity in Non-Celiac Patients

NCT01485341
View directory record Official record
Conditions
Gluten Sensitivity
Interventions
gluten, rice starch
Dietary Supplement
Lead sponsor
University of Campania Luigi Vanvitelli
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 31, 2026, 11:49 PM EDT
Active, not recruiting Phase 3 Interventional

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1160
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Phase 3 Interventional

A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone

NCT00501696
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
4.5 mg Naltrexone, Naltrexone
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 86 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Oct 31, 2026, 11:49 PM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Faces: Choices Study

NCT02409862
View directory record Official record
Conditions
Socioemotional Aging
Interventions
Oxytocin Spray, Placebo Spray
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Oct 31, 2026, 11:49 PM EDT
Withdrawn Phase 4 Interventional

The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study

NCT01663662
View directory record Official record
Conditions
Heart Failure
Interventions
Tolvaptan, placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Not applicable Interventional Results available

Mechanisms of Glucose Lowering Effect of Colesevelam HCl

NCT00596427
View directory record Official record
Conditions
Diabetes
Interventions
Colesevelam HCL, Placebo
Drug
Lead sponsor
Carine Beysen
Industry
Eligibility
30 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Walnut Creek, California • Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Results available

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

NCT03617679
View directory record Official record
Conditions
Metastatic Endometrial Cancer
Interventions
Rucaparib, Placebo Oral Tablet
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Not applicable Interventional

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

NCT05432479
View directory record Official record
Conditions
Infantile Colic
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
The Archer-Daniels-Midland Company
Industry
Eligibility
3 Weeks to 12 Weeks
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Recruiting Phase 3 Interventional

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Phase 2 Interventional Results available

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

NCT02387762
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
acalabrutinib, Placebo
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
17
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 31, 2026, 11:49 PM EDT
Recruiting Not applicable Interventional

Impact of Photobiomodulation (PBM) on Biomarkers of Radiation Lymphedema and Fibrosis in Head and Neck Cancer Patients

NCT06708754
View directory record Official record
Conditions
Radiation Lymphedema, Radiation Fibrosis, Head and Neck Cancer
Interventions
Photobiomodulation (PBM) Therapy, Sham PBM
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Not applicable Interventional Results available

Testing the Efficacy and Mechanisms of an Adapted Resilience Building Intervention in People Aging With HIV

NCT05314088
View directory record Official record
Conditions
Resilience, HIV-1-infection, Stress, Psychological
Interventions
RISE+, Stress Reduction Control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Not listed Phase 2 Interventional

Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor

NCT02724527
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cavosonstat, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 31, 2026, 11:49 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Drug · Other
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

NCT04539041
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
antisense oligonucleotide, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
La Jolla, California • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 11:49 PM EDT
Recruiting Phase 2 Interventional

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

NCT07355296
View directory record Official record
Conditions
Proteinuric Kidney Diseases
Interventions
BI 764198, Placebo matching BI 764198
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
24
States / cities
Huntsville, Alabama • Glendale, California • Granada Hills, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

NCT03490162
View directory record Official record
Conditions
Malaria
Interventions
DM1157, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients

NCT01533688
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Golytely (polyethylene glycol electrolyte lavage solution) and placebo, split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo, split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 31, 2026, 11:49 PM EDT
Terminated No phase listed Observational

An Evaluation of Patient Reported Outcomes and Clinical Outcomes

NCT06092970
View directory record Official record
Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Huntsville, Alabama • San Francisco, California • Stanford, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 31, 2026, 11:49 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Brain and Genetic Predictors of Individual Differences in Pain and Analgesia

NCT03781570
View directory record Official record
Conditions
Pain, Acute
Interventions
Placebo Cream, Control Cream
Behavioral
Lead sponsor
Trustees of Dartmouth College
Other
Eligibility
18 Years to 55 Years
Enrollment
541 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease

NCT00387270
View directory record Official record
Conditions
Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 31, 2026, 11:49 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

NCT04492722
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
AZD5718, Dapagliflozin 10 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Canoga Park, California • La Mesa, California • San Carlos, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 31, 2026, 11:49 PM EDT
Completed Phase 2 Interventional

Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery

NCT01842529
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation, Indications for CABG
Interventions
botulinum toxin injection, 0.9% normal saline injection, Implantable loop recorder
Biological · Device
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 31, 2026, 11:49 PM EDT